Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | MET | P08581 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12663540 | 0.89 | KDR (0.43) | PDGFRBPDGFRAFGFR2KDRMET | |
| SCHEMBL30467929 | 0.88 | PDGFRA (0.69) | PDGFRBPDGFRAFGFR2KDREGFR | |
| SCHEMBL4482576 | 0.88 | PDGFRA (0.69) | PDGFRBPDGFRAFGFR2KDREGFR | |
| SCHEMBL1873879 | 0.88 | AXL (0.55) | PDGFRBPDGFRAFGFR2KDRMET | |
| SCHEMBL14098962 | 0.86 | FGFR2 (0.61) | PDGFRBPDGFRAFGFR2KDRMET | |
| SCHEMBL31678916 | 0.86 | FGFR2 (0.61) | PDGFRBPDGFRAFGFR2KDRMET | |
| SCHEMBL2064387 | 0.86 | FGFR2 (0.61) | PDGFRBPDGFRAFGFR2KDRMET | |
| SCHEMBL14609205 | 0.86 | MET (0.41) | PDGFRBPDGFRAFGFR2KDRMET | |
| SCHEMBL5202698 | 0.86 | KDR (0.61) | PDGFRBPDGFRAKDRMETEGFR | |
| SCHEMBL1889806 | 0.86 | MET (0.48) | PDGFRBPDGFRAFGFR2KDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956138-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-10966987-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200054644-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-10398703-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-9877970-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9827248-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1384712-B1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BREWERY (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6797823-B1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1384712-A1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1153920-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BREWERY (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1153920-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966987-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | PDGFRB 2819/4885PDGFRA 3408/4885FGFR2 2328/4885 |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | CYTH3, NQO2, NRAS | PDGFRB 3304/4885PDGFRA 3108/4885FGFR2 4751/4885 |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | PDGFRB 2819/4885PDGFRA 3408/4885FGFR2 2328/4885 |
| US-20200054644-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | PDGFRB 2819/4885PDGFRA 3408/4885FGFR2 2328/4885 |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | PDGFRB 2819/4885PDGFRA 3408/4885FGFR2 2328/4885 |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | RABL3, NRAS, CYTH3 | PDGFRB 3503/4885PDGFRA 3103/4885FGFR2 4699/4885 |
| US-10398703-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | PDGFRB 2819/4885PDGFRA 3408/4885FGFR2 2328/4885 |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | FLT3, TYRO3, ABL1 | PDGFRB 159/4885PDGFRA 229/4885FGFR2 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.